RESEARCH CENTER- GASTROENTEROLOGY
This has been a great experience! Kendra, Alyssa, Susie, and Kelly are very professional, I'm glad to be a participant!
Being part of the study I feel valued and respected. Susie and the staff always greet me with a smile and are very welcoming. It is very rewarding.
The staff are amazing and knowledgeable, facilities are clean and comfortable. I've had a very positive experience. I wanted to learn more about my disease and help my body. I'm glad I took this step.
PAID CLINICAL TRIALS
LEARN MORE
CONTACT US
PREMIER GASTROENTEROLOGY RESEARCH CENTER IN KANSAS
Susie Roeder, RT, RPFT, CCRC | 785-295-0938
KMC Research Center, Gastroenterology Division
2200 SW 6th Ave
Topeka KS 66606
KMC RESEARCH CENTER
GASTROENTEROLGY CURRENT CLINICAL TRIALS:
NASH TRIALS:
1. A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Steatohepatitis (NASH) stages 1,2,3 to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation.
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with Stages 1,2,3 NASH, ages 18 and older
Duration: Up to 54 Months
Compensation: Yes
2. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD1).
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with NAFLD, ages 18 and older
Duration: 52 Week Treatment
Compensation: Yes
3. A Phase 2B study to evaluate the safety, tolerability and efficacy of Viking (VK2809) in patients with NASH with fibrosis.
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with NASH with fibrosis, ages 18 and older
Duration: 52 Week Treatment
Compensation: Yes
4. A phase 2, dose finding study to evaluate efficacy and safety of PF-06865571 alone and when co-administered with PF-05221304 in patients with NASH with fibrosis stage 2 or 3.
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with NASH with fibrosis stage 2 or 3, ages 18 and older
Duration: 42 Week Treatment
Compensation: Yes
5. A phase 2 study to evaluate efficacy, safety and tolerability of HM15211 in patients with biopsy confirmed NASH.
Type of Study: Injection administered subcutaneously (Chance of placebo)
Who: Individuals with NASH confirmed by biopsy, ages 18 and older
Duration: 52 Week Treatment
Compensation: Yes
6. A phase 3a (NASH) NN9931-4553 - The effect of semaglutide in subjects with NASH.
Type of Study: Injection administered subcutaneously (Chance of placebo)
Who: Individuals with NASH confirmed by biopsy, ages 18 and older
Duration: 72 Week Treatment
Compensation: Yes
7. A phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Efruxifermin in NASH.
Type of Study: Injection administered subcutaneously (Chance of placebo)
Who: Individuals with NASH confirmed by biopsy, ages 18 and older
Duration: 24 Week Treatment
Compensation: Yes
8. A phase 2b, multi-centered, double-blind, randomized, placebo-controlled study of the safety and efficacy of TVB-2640 in subjects with NASH.
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with NASH confirmed by biopsy, ages 18 and older
Duration: 12 Week Treatment
Compensation: Yes
CELIAC DISEASE TRIALS:
8. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Larazotide for the Relief of Persistent Symptoms in Patients with Celiac Disease on a Gluten-Free Diet (GFD).
Type of Study: Investigational medicine (Chance of placebo)
Who: Individuals with Celiac Disease on GFD, ages 18 and older
Duration: Minimum 12 Weeks
Compensation: Yes
ESOPHAGEAL VARICES TRIALS:
9. A phase 2b/3 study to evaluate the efficacy and safety of Belapectin for the prevention of Esophageal varices in NASH cirrhosis.
Type of Study: Injection administered subcutaneously (Chance of placebo)
Who: Individuals with confirming nonalcoholic steatohepatitis (NASH) cirrhosis, ages 18 and older
Duration: 78 Week Treatment
Compensation: Yes
**CLOSED TO ENROLLMENT** A Phase 3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Prevention of Recurrent Clostridium Difficile Infection (CD3-2).
**CLOSED TO ENROLLMENT** A phase 3 clinical trial to assess the safety and efficacy of Cenicriviroc (CVC) for the treatment of NASH in adult patients.
**CLOSED TO ENROLLMENT** A phase 3 study to evaluate the efficacy of a new oral medication for Gastroesophageal Reflux Disease (GERD) in patients who are also receiving PPI.
**CLOSED TO ENROLLMENT** A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relamorelin in Patients with Diabetic Gastroparesis.
*There are three separate arms of this study: short term, long term, and one arm for patients that have fewer episodes of vomiting.
**CLOSED TO ENROLLMENT** A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH).
**CLOSED TO ENROLLMENT** A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Adult Subjects with Compensated Cirrhosis Due to Nonalcholic Steatohepatitis (NASH).
**CLOSED TO ENROLLMENT** A Phase 3, 3 part study to investigate the efficacy and safety of Dupilumab in adult and adolescents with Eosinophilic Esophagitis (EoE).
**CLOSED TO ENROLLMENT** A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis.
**CLOSED TO ENROLLMENT** A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Operationally Seamless 2b/3, Parallel-Group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease.
On the Horizon:
Idiopathetic Gastroparesis Study - Phase 3
GERD
Eosinophilic Esophagitis
Diabetic Gastroparesis
For a complete list of trials KMC is participating in, click here.
Interested in participating in or learning more about a clinical trial? Please call Susie Roeder at 785-295-0938.